Clinical Trial Applications: Filter, Search, and view applications
# | Protocol No | Study Title | Investigator(s) & Site(s) | |
---|---|---|---|---|
16. |
ECCT/24/07/05 | Gates MRI TBV02-301 A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults. |
Principal Investigator(s) 1. Dr Bernhards Ogutu Site(s) in Kenya 1. HOMA BAY COUNTY TEACHING AND REFERRAL HOSPITAL SITE (Homa Bay county) |
View |
17. |
ECCT/24/07/04 | AMC-114 A Phase III, Randomized, Open-Label, Non-Inferiority Study of Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma in Resource-Limited Settings |
Principal Investigator(s) 1. Dr. Naftali Busakhala Site(s) in Kenya Moi University Clinical Research Center |
View |
18. |
ECCT/24/07/03 | RVF003 Trial Phase 2 trial to assess the immunogenicity and safety of the ChAdOx1 RVF vaccine against Rift Valley fever in adults in Kenya |
Principal Investigator(s) 1. George Warimwe Site(s) in Kenya KEMRI-Wellcome Trust Research Programme |
View |
19. |
ECCT/24/07/01 | LCCC 2330 Feasibility of intravaginal artesunate as adjuvant HPV & cervical precancer treatment among women living with HIV in Kenya: A Phase II trial |
Principal Investigator(s) 1. Chemtai Mungo Site(s) in Kenya Cervical Cancer Screening Program (CCSP) Lumumba Sub-County Hospital |
View |
20. |
ECCT/24/06/07 | Gates MRI TBV02-301 A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults. |
Principal Investigator(s) 1. Charity Wambui Kanyoro Site(s) in Kenya 1. Moi University Clinical Research Centre (Uasin Gishu county) |
View |